By clicking below you acknowledge that you are navigating away from temaetfs.com and will be connected to temafunds. Tema Global Limited manages both domains. Please take note of Tema's privacy policy, terms of use, and disclosures that may vary between sites.
Start investing now
.svg){kind=small}
Start investing now
Invest directly by choosing one of the brokers below
Start investing now
Invest directly by choosing one of the brokers below
Start investing now
Invest directly by choosing one of the brokers below
Start investing now
Invest directly by choosing one of the brokers below
Start investing now
Invest directly by choosing one of the brokers below
Start investing now
Invest directly by choosing one of the brokers below
Start investing now
Invest directly by choosing one of the brokers below
Your are leaving temaetfs.com
Which fund are you interested in?
Life Sciences
HRTS 
GLP-1, Obesity & Cardiometabolic ETF
CANC
Oncology ETF
MNTL
Neuroscience and Mental Health ETF
Strategic Equity
TOLL
Monopolies and Oligopolies ETF
RSHO
American Reshoring ETF
VOLT
Tema Electrification ETF
LUX
Luxury ETF
.svg){kind=small}
.svg){kind=icon}
Back
Why CANC ETF?
Impact
Investors can provide capital to companies pioneering cures and early detection of cancer
Innovation
The life sciences industry is still in the early stages of a revolution in oncology innovations - from CAR-T cell therapies to bi-specific antibodies - powered by biological insights and growing capabilities
Research Expertise
The fund conducts deep and comprehensive research, in an effort to identify those companies that deliver breakthrough solutions at attractive valuations
Growth
Oncology is an increasingly prioritized therapeutic class with treatment spend expected to grow substantially, driven by an aging population; this secular growth trend also tends to be insulated from economic cycles
Uncorrelated
Performance of many biotechnology companies relies on clinical success which is an uncorrelated source of return
Fund Overview
Fund Details
As of December 20, 2024
Primary Exchange
Nasdaq
Ticker
CANC
AuM (USD)
$45,108,872
# of Holdings
51
Fund Inception Date
08/14/23
Gross Expense Ratio
0.99%
Net Expense Ratio*
0.75%
Implied Liquidity (# of shares)
ETF Implied liquidity is a representation of how many shares can potentially be traded daily in an ETF as portrayed by the creation unit. This is defined as the smallest value of the IDTS (Implied Daily Tradable Shares) for each holding in the creation unit.
1,365,278
Implied Liquidity (USD)
ETF Implied liquidity is a representation of how many shares can potentially be traded daily in an ETF as portrayed by the creation unit. This is defined as the smallest value of the IDTS (Implied Daily Tradable Shares) for each holding in the creation unit.
$33M
Shares Outstanding
1,850,000
Investment Advisor
Tema Global Limited
Sub-Investment Advisor
NEOS Investments, LLC
*Contractual expense cap for net expense ratio of 0.75% is in effect through 06/28/2027
Fund Summary
The actively managed Tema Oncology ETF seeks to provide long-term growth by investing in companies operating in the oncology industry. Cancer is the second deadliest killer but is on the brink of a revolution in therapeutics and diagnosis. Genetic sequencing and other forces are leading to a productivity surge, with oncology leading the way in new drug approvals. The growing complexity of scientific discovery, regulation and a surge in investment opportunities requires expertise to navigate this exciting chapter in human development.
Portfolio Manager
Investment Partner
David K. Song, MD, PhD, CFA
David Song, Investment Partner, has led biotechnology and healthcare investment teams throughout his extensive 25-year career at Rockefeller Capital Management, Millennium and Balyasny. He studied Economics and Biochemistry at Yale, is a medical doctor and has a PhD in Applied Economics from Wharton.
How does the Tema CANC ETF fit in a portfolio?
Investment Style Box
Source: Tema. The investment style Box reveal’s a fund’s investment strategy by showing its investment style and market capitalization based on the fund’s portfolio holdings.
Potential Portfolio
Equity Allocation
3-5%
Equity Satellite
CANC ETF
Equity core
Where could a position be funded from?
-
Could be a more targeted alternative to existing healthcare or biopharma exposure in a portfolio.
-
Provides a balanced exposure across key oncology areas and company risk profiles.
- Could replace a satellite or a growth-oriented position.
FAQ
What companies are included in Tema's Oncology ETF?
How many holdings are in the Tema Oncology ETF?
What is an oncology ETF?
How do oncology ETFs work?
How big is the oncology market?
Is cancer etf a good investment?
What are the benefits of investing in an oncology ETF?
What factors should I consider before investing in an oncology ETF?
Are oncology ETFs focused on specific types of cancer treatments?
How does an ETF focused on oncology differ from a general healthcare ETF?
What are the risks associated with investing in an emerging cancer ETF?
Can I invest in cancer research through cancer ETFs?
What role does biotechnology play in cancer ETFs?
How to buy
*Neither Tema Global Limited nor undefined ETF are affiliated with these financial services firms. Their listing should not be viewed as a recommendation or endorsement.